Pharmacogenomic biomarkers in coronary artery disease: a narrative review

Biomark Med. 2024 Mar 8. doi: 10.2217/bmm-2023-0476. Online ahead of print.ABSTRACTCoronary artery disease (CAD) has a high mortality rate. Despite various therapeutic targets, non-responsiveness to drugs remains a prevalent issue. Pharmacogenomics assesses the way an individual's genetic attributes affect their likely response to drug therapy. Single-nucleotide polymorphisms play a crucial role in determining these outcomes. This review offers an overview of single-nucleotide polymorphisms investigated in clinical studies and their associations with drug response/nonresponse in the treatment of CAD. A total of 104 studies of whole sets of chromosomes and several genes were explored. A total of 161 polymorphisms exhibited associations with drug response/nonresponse in CAD across diverse ethnic populations. This pool can serve as a pharmacogenomic biomarker for predicting response to drug therapy in patients with CAD.PMID:38456296 | DOI:10.2217/bmm-2023-0476
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Authors: Source Type: research